Media coverage about Cutera (NASDAQ:CUTR) has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cutera earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 46.9132650558584 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have effected Accern’s analysis:

A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Cutera from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Roth Capital lifted their target price on Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, September 12th. Maxim Group downgraded Cutera from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Finally, TheStreet raised Cutera from a “c” rating to a “b” rating in a research report on Friday, August 18th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $37.33.

Cutera (NASDAQ:CUTR) opened at $42.45 on Friday. The firm has a market capitalization of $576.37, a P/E ratio of 53.33, a price-to-earnings-growth ratio of 1.73 and a beta of 0.49. Cutera has a 12-month low of $13.70 and a 12-month high of $44.40.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.34. The firm had revenue of $38.17 million for the quarter, compared to the consensus estimate of $34.82 million. Cutera had a return on equity of 18.73% and a net margin of 7.99%. The business’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.12 earnings per share. equities research analysts anticipate that Cutera will post 0.55 earnings per share for the current fiscal year.

Cutera declared that its Board of Directors has authorized a share repurchase program on Monday, August 7th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

In other Cutera news, EVP Ronald J. Santilli sold 1,068 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $33.20, for a total transaction of $35,457.60. Following the transaction, the executive vice president now owns 87,253 shares of the company’s stock, valued at $2,896,799.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Ronald J. Santilli sold 28,519 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $34.01, for a total value of $969,931.19. Following the transaction, the executive vice president now directly owns 75,253 shares in the company, valued at approximately $2,559,354.53. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,009 shares of company stock worth $2,438,915. Company insiders own 11.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-cutera-cutr-stock-price/1696852.html.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Insider Buying and Selling by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.